Emerita Provides Response to Demand Letter

TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV: EMO) (OTCQX: EMOTF) (FSE: LLJA) confirms that on May 14, 2026 it received a demand letter from legal counsel to PM Super Fund and the sole director of the trustee of the Super Fund, Wayne Peters, requesting that the Company initiate legal proceedings in connection with the Falcon Litio property (the “Demand Letter”).

The Company has tasked its Special Committee, comprised of independent directors, to direct the Company’s review of the Demand Letter and the allegations set out therein and determine the appropriate course of action. The Special Committee has commenced its review and intends to complete this work expeditiously.

About Emerita Resources Corp.

Emerita is a natural resource company engaged in the acquisition, exploration, and development of mineral properties in Europe, with a primary focus on exploring in Spain. The Company’s corporate office and technical team are based in Sevilla, Spain with its registered office in Toronto, Canada.

For further information, contact:

Ian Parkinson
+1 647 910-2500 (Toronto)
[email protected]
www.emeritaresources.com

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, the Demand Letter and allegations therein, potential claims against the Company and its directors and officers, the costs and timing of litigation and the Company's future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Emerita, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; the actual results of current exploration activities; risks associated with operating in foreign jurisdictions; ability to successfully integrate the purchased properties; foreign operations risks; and other risks inherent in the mining industry. Although Emerita has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Emerita does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: Emerita Resources Corp.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Island Passage Exploration and Isina Resource Holdings Announce Land Access and Compensation Payments of 200,000 Kina made to customary landowners from work conducted on the EL02 Project Bougainville
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides Updates on Positive June Sales Targets; Recaps June 16 Robotics and Education Ecosystem Product Launch; Previews Ju
• Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma